Journals / MN Kardiyoloji / 2010 / Cilt: 17 - Sayı: 5

Cardiovascular drugs and New-onset diabetes risk

Kardiyovasküler ilaçlar ve yeni diyabet gelişim riski

Pages
343–347
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Awareness about the adverse metabolic effects of these drugs would be beneficial for close follow- up and suitable treatment, especially in patients with other risk factors for diabetes such as obesity and sedentary life style.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Coronary heart disease, hypertension and diabetes frequently coexist in the same patient but certain cardiovascular drugs that are used in the treatment of these patients (beta blockers, thiazide diuretics, statins, and niacin) might increase the risk of new-onset diabetes or worsen glycemic control.
📊
Key Findings & Data:Coronary heart disease, hypertension and diabetes frequently coexist in the same patient but certain cardiovascular drugs that are used in the treatment of these patients (beta blockers, thiazide diuretics, statins, and niacin) might increase the risk of new-onset diabetes or worsen glycemic control.
💡
Conclusion & Impact:Awareness about the adverse metabolic effects of these drugs would be beneficial for close follow- up and suitable treatment, especially in patients with other risk factors for diabetes such as obesity and sedentary life style.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Coronary heart disease, hypertension and diabetes frequently coexist in the same patient but certain cardiovascular drugs that are used in the treatment of these patients (beta blockers, thiazide diuretics, statins, and niacin) might increase the risk of new-onset diabetes or worsen glycemic control. Awareness about the adverse metabolic effects of these drugs would be beneficial for close follow- up and suitable treatment, especially in patients with other risk factors for diabetes such as obesity and sedentary life style.

Özet

Koroner kalp hastalığı, hipertansiyon ve diyabet sıklıkla aynı hastada birlikte bulunmakta ancak bu hastaların tedavisinde kullanılan belli bazı kardiyovasküler ilaçlar (beta blokerler, tiyazid diüretikler, statinler ve niasin) yeni diyabet gelişim riskini arttırabilmekte veya mevcut glisemik kontrolü güçleştirmektedir. Bu ilaçların istenmeyen metabolik etkilerinin bilinmesi, bu ilaçları kullanmak zorunda olan ve özellikle diyabet gelişimi açısından obezite ve sedanter yaşam tarzı gibi diğer riskleri de taşıyan hastaların daha yakından takibini ve gerekirse uygun tedavisini sağlayacaktır.

🔖

Cite This Article

ÇAĞLI, K. E., BAŞAR, N., ÖZCAN, F. (2010). Cardiovascular drugs and New-onset diabetes risk. MN Kardiyoloji, Cilt: 17 - Sayı: 5, 343–347. https://ajindex.com/articles/297503

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010;121:e46- e215
  2. Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum. J Am Coll Cardiol 2009;53(5 Suppl):28-34
  3. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-90
  4. Cooper-Dehoff R, Cohen JD, Bakris GL, et al. INVEST Investigators. Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]). Am J Cardiol 2006;98:890-4
  5. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86
  6. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989;298:1152-7
  7. Nesto RW. Diabetes and Heart Disease. In: Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E. Editors. Braunwald’s Heart Disease. A Textbook of Cardiovascular Medicine, Philadelphia, PA: Saunders Elsevier, 2008; 1547-60
  8. Bakris GL, Fonseca V, Katholi RE, et al. GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004; 292:2227-36
  9. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-107
  10. Bangalore S, Parkar S, Grossman E, Messerli FH. A metaanalysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62
  11. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7
  12. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardio - vascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007;50:563-72
  13. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Tas